A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

Status:
Active, not recruiting

Trial end date:
2023-03-02

Target enrollment:

Participant gender:

To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.

Phase 4

Bristol-Myers Squibb

Antibodies, Monoclonal
Ipilimumab
Nivolumab